HC Wainwright cut shares of Adlai Nortye (NASDAQ:ANL - Free Report) from a buy rating to a neutral rating in a research note published on Monday, MarketBeat reports.
Adlai Nortye Trading Up 1.9%
Shares of Adlai Nortye stock traded up $0.03 during midday trading on Monday, hitting $1.64. The company had a trading volume of 6,039 shares, compared to its average volume of 12,854. The business's 50 day simple moving average is $1.92 and its two-hundred day simple moving average is $2.12. Adlai Nortye has a 1-year low of $1.10 and a 1-year high of $7.08.
Adlai Nortye Company Profile
(
Get Free Report)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Featured Articles
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
